Alroughani R, et al. - The intention of the experts was to scrutinize the safety, efficacy, and pharmacokinetics of dimethyl fumarate (DMF) in pediatric patients with multiple sclerosis (MS). Findings reported that DMF treatment caused a reduction in magnetic resonance imaging (MRI) activity in pediatric patients. Consistent pharmacokinetic and safety profiles were yielded with those in adults. The inference drawn was that DMF served as a potential treatment option for pediatric MS.